Table 2.
Tumor cell line inhibitory activity GI50 (nM) of 7(NCI).
| Panel/ Cell line | GI50 (nM) |
|---|---|
| Leukemia | |
| CCRF-CEM | 31.2 |
| HL-60(TB) | 150 |
| K-562 | 366 |
| MOLT-4 | 66.1 |
| RPMI-8226 | 489 |
| SR | 484 |
| NSCLC | |
| A549/ATCC | 43.4 |
| EKVX | 2710 |
| HOP-62 | 654 |
| HOP-92 | 18100 |
| NCI-H226 | 2140 |
| NCI-H23 | 565 |
| NCI-H322M | 1350 |
| NCI-H460 | 19.3 |
| NCI-H522 | 622 |
| Colon Cancer | |
| COLO 205 | 638 |
| HCT-116 | 38.1 |
| HCT-15 | 434 |
| KM12 | 330 |
| SW-620 | 63.0 |
| CNS Cancer | |
| SF-268 | 86.2 |
| SF-295 | 547 |
| SF-539 | 381 |
| SNB-19 | 113 |
| SNB-75 | 5030 |
| U251 | 184 |
| Prostate Cancer | |
| PC-3 | 715 |
| DU-145 | 212 |
| Melanoma | |
| LOX IMVI | 308 |
| MALME-3M | >10000 |
| M14 | 431 |
| SK-MEL-2 | 558 |
| SK-MEL-28 | 1510 |
| SK-MEL-5 | 513 |
| UACC-257 | 84.5 |
| UACC-62 | 641 |
| Ovarian cancer | |
| IGROVI | 287 |
| OVCAR-3 | 216 |
| OVCAR-4 | 2090 |
| OVCAR-8 | 216 |
| SK-OV-3 | 2090 |
| Renal Cancer | |
| 786 - 0 | 514 |
| A498 | 2490 |
| ACHN | 3420 |
| CAKI-1 | 1080 |
| RXF 393 | 2910 |
| SN12C | 189 |
| TK10 | 2150 |
| UO-31 | 790 |
| Breast Cancer | |
| MCF7 | 73.4 |
| NCI/ADR-RES | 787 |
| MDA-MB-231/ATCC | 641 |
| HS 578T | 2220 |
| MDA-MB-435 | 554 |
| BT-549 | 2830 |
| T-47D | 2900 |